BIOCON 1. Assuming Biocon receives approval for BioMab‚ should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate on the various elements of your action plan. 2. How big is the current and future market opportunity in BIOMAb? The current market opportunity of BIOMAb is limited but the future is going to be bigger. In 2004‚ the 5-year prevalence (number of people diagnosed with cancer and still alive after 5 years) was 375‚000 and the incidence (new cases
Premium Oncology Cancer Chemotherapy
Biocon Limited 1. Assuming Biocon receives approval for BioMAb‚ should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate the various elements of your action plan. Even if the Drug Controller General of India (DCGI) grants permission for BIOMAb in fall 2006‚ Biocon should still conduct phase 3 trials before launching. Both Biocon and Clinigene are new to the industry and strong reputations have yet to be developed. Therefore‚ Biocon must means make sure BIOMAb
Premium Oncology Cancer Chemotherapy
Biocon: Launching a New Cancer Drug in India Section E Group 5 Ankita Khandelwal (255) Bojja Raghavendar Reddy (265) Hitesh Chopra (275) Nikhil Singh Rawat (285) Raghavan K. V. (295) Vaibhav Saxena (305) Situation Analysis: • Biocon is an Indian Drug company that has evolved over the years: ▪ It was an enzyme manufacturer for food industry and developed expertise
Premium Oncology Cancer Chemotherapy
Biocon Case Assignment Questions 1. Assuming Biocon receives approval for BIOMAb‚ should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate the various elements of your action plan. If Biocon receives approval for BIOMAb‚ the management team will need to carefully consider what the best course of action is moving forward. If the company elects to launch the drug immediately‚ they will be able to have the first mover advantage‚ reaching the market before their
Premium Pharmaceutical industry Oncology First-mover advantage
Biocon Ltd. Building a Biotech Powerhouse Case analysis -Rajdeep Desai Introduction: Established in 1978‚ Biocon Limited is Asia’s premier biotechnology company and India’s largest biotechnology company by revenue. It is the only Asian company among the top 25 in global biopharma. Biocon is called as Poster child of Biotech in India. The Group‚ promoted by Ms. Kiran Mazumdar Shaw‚ is a fully-integrated‚ innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and
Premium Clinical trial Biotechnology Pharmaceutical industry
an Indian public-listed company BIOCON Final Project Report Contents Background 3 Subsidiary Companies 4 Products and Services 4 The Auditors report 5 The Director’s Report 6 Accounting Policies 7 Balance sheet 14 Cash flow analysis 18 ANNEXURES 21 Ratio Analysis 23 New Terminologies 29 References 30 Background Established in 1978‚ Biocon is India ’s premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company
Premium Balance sheet Asset Income statement
Title II Eligibility Period ISSUE The DDS proposes allowance for this claimant with an EOD of 6/30/16. The evidence in file shows a later onset date is warranted and the claimant was not insured for title II benefits at the time the disability began. CASE DISCUSSION & POLICY ANALYSIS (INCLUDING SPECIFIC REFERENCES) The claimant is a 31-year old filing a concurrent claim with an AOD of 07/25/2012 due to Psoriatic arthritis‚ cataracts‚ hepatitis C‚ s sesamoiditis‚ depression‚ anxiety‚ iritis‚ pilonidal
Premium Patient Medicine Family
Case#4- Federating Insurance: Targeting Small Businesses 1. When looking at an automobile industry the Federated macrosegmentation would be taking a company like BMW and looking at the market segments in a broader view. For example‚ the owner of the branch must make sure their employees are happy with their job. The macrosegmentation of this would be employee performance. Federated plays a role in this because with great performance comes incentives. Federate gives insurance incentives to BMW
Premium Customer service Customer Good
STRATEGIC SWOT ANALYSIS: Strength: The strengths of Biocon are * Financial Leverage – Biocon has maintained a constant Debt/ Equity ratio between 0.11-0.12[1] in the last 5 years‚ which gives it a financial leverage‚ thus letting the share holders enjoy the earnings and also makes the organization financially strong. * Skills in Enzymes – Biocon with its recombinant DNA technology has managed to achieve a different share in the industry‚ its products like Insugen from recombinant human
Premium Biotechnology DNA Chemotherapy
Harvard Business Case Analysis How would you categorize Kearney’s commitment to the company? How might you change or maintain this commitment? Eugene Kearney is very committed to Old Colony Associates (OCA). Kearney is committed in that he has been with the company for 13 years‚ loves going to work every day and aspires to maintain a higher level management position. However‚ he clearly needs to make improvements to his current level of commitment to OCA. Kearney needs to realize that commitment
Premium Management Employment